Flow cytometry as a prognostic method for the identification of adenomatous hyperplasia at risk of developing endometrial carcinoma

Anticancer Research

Volumn 18, Issue 6 B, 1998, Pages 4611-4612

  Lindahl, Bengt ^a   Willén, Roger ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adenomatous hyperplasia; Endometrial carcinoma; Flow cytometry; Prognosis

Indexed keywords

DNA;

ADENOMA; ANEUPLOIDY; ARTICLE; CELL CYCLE S PHASE; CLINICAL ARTICLE; DIPLOIDY; DNA DETERMINATION; ENDOMETRIUM CARCINOMA; FEMALE; FLOW CYTOMETRY; HIGH RISK POPULATION; HUMAN; PRIORITY JOURNAL; PROGNOSIS;

ADENOMA; ANEUPLOIDY; DIPLOIDY; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; S PHASE; TIME FACTORS;

EID: 0032420864     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Backer J: Zwei Falle von Carcinoma corporis uteri. Zentralblatt fur Gynakologi 28:735-736, 1904.
2. Cullen T: Cancer of the uterus. 1900.
3. Lindahl B, Willen R: Spontaneous endometrial hyperplasia. A prospective, 5 year follow-up of 246 patients after abrasio only, including 380 patients followed-up for 2 years. Anticancer Res 14: 2141-2146, 1994.
4. Janicek MF, Rosenshein NB: Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia Gynecologic Oncology 52: 373-378, 1994.
5. Baak JPA, Wisse-Brekelmans ECM, Fleege JC, van der Putten HWHM, Bezemer PD: Assessment of the risk on endometrial cancer in hyperplasia, by means of morphological and morphometrical features. Path Res Pract 188: 856-859, 1992.
6. Fox H: Endometrial hyperplasia. Current diagnostic. Pathol 1: 151-157, 1994.
7. Lindahl B, Willen R: Endometrial hyperplasia. Clinico-pathological considerations of a prospective randomised study after abrasio only or high-dose gestagen treatment. Results of 2 year follow-up of 292 patients. Anticancer Res 11: 403-406, 1991.
8. Lindahl B, Willén R: Spontaneous endometrial hyperplasia. A 5 year follow-up of 82 patients after high-dose gestagen treatment. Anticancer Res 14: 2831-2834, 1994.
9. Lindahl B, Willen R: Steroid receptor concentrations as a prognostic factor in atypical endometrial hyperplasia. Anticancer Res 18: in press, 1998.
10. Lindahl B, Ranstam J, Norgren A, Willen R: Identification of highrisk groups in endometrial carcinoma stage I-II. A combination of DNA- and steroid receptor-measurements identifies early deaths from disease. Anticancer Res 15: 1095-1100, 1995.
11. Poulsen HE, Taylor CW, Sobin LH and pathologists in nine countries: Histologic typing of female genital tract tumours. In: International Histological Classification of tumours No. 13. WHO 1975.